NADPH Alkenal/One Oxidoreductase Activity Determines Sensitivity of Cancer Cells to the Chemotherapeutic Alkylating Agent Irofulven

Clinical Cancer Research

Volumn 10, Issue 4, 2004, Pages 1492-1499

  Dick, Ryan A ^a   Yu, Xiang ^a   Kensler, Thomas W ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CYCLOPROPANE DERIVATIVE; CYTOTOXIC AGENT; GLUTATHIONE; ILLUDIN M; ILLUDIN S; IROFULVEN; KETONE DERIVATIVE; OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE ALKENAL OXIDOREDUCTASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE ALKENONE OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CHEMICAL BOND; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPATHOGENIC EFFECT; DRUG ACTIVATION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SCREENING; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ASSAY; EXPRESSION VECTOR; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROGENATION; MUSHROOM; OMPHALOTUS ILLUDENS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TANDEM MASS SPECTROMETRY;

ALCOHOL OXIDOREDUCTASES; ALKYLATING AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CELL LINE; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTATHIONE; HUMANS; KETONES; KINETICS; MASS SPECTROMETRY; MODELS, CHEMICAL; SENSITIVITY AND SPECIFICITY; SESQUITERPENES; TIME FACTORS; TRANSFECTION;

EID: 1642293264     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0162     Document Type: Article

References (20)

1. Pratt, W. B. The Anticancer Drugs, 2nd Ed., p. 352. New York: Oxford University Press, 1994.
2. Powis, G. Anticancer Drugs: Reactive Metabolism and Drug Interactions, 1st Ed., p. 444. Oxford, England: Pergamon Press, 1994.
3. Sato, Y., Kashimoto, S., MacDonald, J. R., and Nakano, K. In vivo antitumour efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumour xenograft models including several lung and gastric tumours. Eur. J. Cancer, 37: 1419-1428, 2001.
4. Leggas, M., Stewart, C. F., Woo, M. H., Fouladi, M., Cheshire, P. J., Peterson, J. K., Friedman, H. S., Billups, C., and Houghton, P. J. Relation between irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts. Clin. Cancer Res., 8: 3000-3007, 2002.
5. MacDonald, J. R., Muscoplat, C. C., Dexter, D. L., Mangold, G. L., Chen, S. F., Kelner, M. J., McMorris, T. C., and Von Hoff, D. D. Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res., 57: 279-283, 1997.
6. Britten, C. D., Hilsenbeck, S. G., Eckhardt, S. G., Marty, J., Mangold, G., MacDonald, J. R., Rowinsky, E. K., Von Hoff, D. D., and Weitman, S. Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model. Cancer Res., 59: 1049-1053, 1999.
7. Bayes, M., Rabasseda, X., and Prous, J. R. Gateways to clinical trials. Methods Find Exp. Clin. Pharmacol., 25: 145-168, 2003.
8. McMorris, T. C., Kelner, M. J., Wang, W., Yu, J., Estes, L. A., and Taetle, R. (Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties. J. Nat. Prod., 59: 896-899, 1996.
9. McMorris, T. C., and Anchel, M. Fungal metabolites. The structures of the novel sesquiterpenoids illudin-S and -M. J. Am. Chem. Soc., 87: 1594-1600, 1965.
10. Kelner, M. J., McMorris, T. C., Montoya, M. A., Estes, L., Rutherford, M., Samson, K. M., and Taetle, R. Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells. Cancer Chemother. Pharmacol., 40: 65-71, 1997.
11. Kelner, M. J., McMorris, T. C., and Taetle, R. Preclinical evaluation of illudins as anticancer agents: basis for selective cytotoxicity. J. Natl. Cancer Inst. (Bethesda), 82: 1562-1565, 1990.
12. Kelner, M. J., McMorris, T. C., Beck, W. T., Zamora, J. M., and Taetle, R. Preclinical evaluation of illudins as anticancer agents. Cancer Res., 47: 3186-3189, 1987.
13. Tanaka, K., Inoue, T., Kadota, S., and Kikuchi, T. Metabolism of illudin S, a toxic principle of Lampteromyces japonicus, by rat liver. I. Isolation and identification of cyclopropane ring-cleavage metabolites. Xenobiotica, 20: 671-681, 1990.
14. McMorris, T. C., Elayadi, A. N., Yu, J., Hu, Y., and Kelner, M. J. Metabolism of antitumor hydroxymethylacylfulvene by rat liver cytosol. Drug Metab. Dispos., 27: 983-985, 1999.
15. McMorris, T. C., Kelner, M. J., Wang, W., Moon, S., and Taetle, R. On the mechanism of toxicity of illudins: the role of glutathione. Chem. Res. Toxicol., 3: 574-579, 1990.
16. Tanaka, K., Inoue, T., Kadota, S., and Kikuchi, T. Metabolism by rat liver cytosol of illudin S, a toxic substance of Lampteromyces japonicus. II. Characterization of illudin S-metabolizing enzyme. Xenobiotica, 22: 33-39, 1992.
17. Dick, R. A., Kwak, M. K., Sutter, T. R., and Kensler, T. W. Antioxidative function and substrate specificity of NAD(P)H-dependent alkenal/one oxidoreductase. A new role for leukotriene B4 12-hydroxydehydrogenase/15-oxoprostaglandin 13-reductase. J. Biol. Chem., 276: 40803-40810, 2001.
18. Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minna, J. D., and Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res., 47: 936-942, 1987.
19. Baillie, T. A., and Kassahun, K. Biological reactive intermediates in drug discovery and development: a perspective from the pharmaceutical industry. Adv. Exp. Med. Biol., 500: 45-51, 2001.
20. Yokomizo, T., Ogawa, Y., Uozumi, N., Kume, K., Izumi, T., and Shimizu, T. cDNA cloning, expression, and mutagenesis study of leukotriene B4 12-hydroxydehydrogenase. J. Biol. Chem., 271: 2844-2850, 1996.